936002-90-3

Upstream product

• 936002-81-2 N-(3-{(R)-2-[1,1-dimethyl-3-(5-nitroindol-1-yl)propylamino]-1-hydroxyethyl}phenyl)benzenesulphonamide 

Downstream Products

• 1075751-45-9 N-(1-{3-[(R)-2-[3-(phenylsulphonylamino)phenyl]-2-hydroxyethylamino]-3-methylbutyl}-1H-indol-5-yl)-2-(2-aminothiazol-4-yl)acetamide 
• 936003-03-1 N-(1-{3-[(R)-2-[3-(phenylsulphonylamino)phenyl]-2-hydroxyethylamino]-3-methylbutyl}-1H-indol-5-yl)hexanoic acid amide hydrotrifluoroacetate 
• 936004-33-0 benzyl [(1S,2S)-1-(1-{3-[(R)-2-[3-(phenylsulphonylamino)phenyl]-2-hydroxyethylamino]-3-methylbutyl}-1H-indol-5-ylcarbamoyl)-2-methylbutyl]carbamate hydroformate 

Relevant academic research and scientific papers

3- (SULPHONYLAMINO) -PHENYL-2 -HYDROXY-ETHYLAMINO DERIVATIVES USEFUL AS BETA-AGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS

The present invention relates to compounds of general formula (I), wherein the groups A, L, R1 and R2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, mixtures thereof, so

Indol-containing beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions

The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 and R2 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates,